Schroder UK Public Private Trust (SUPP) - formerly disgraced Neil Woodford’s Patient Capital Trust (WPCT) - has released its FY19 numbers and the report is truly a dog’s breakfast. It is a shambles: the manager has gone but the board should be sacked at once.
This is an amaingly honest yet utterly dishonest admission from Schroders which managesthe Schroders UK Public Private Trust (SUPP), the dog formerly known as the Woodford Patient Capital Trust (WPCT). It is also a damning indictment of the disgraced Neil Woodford. Schroders has published a new Key Information Document, a KID.
The dog’s breakfast that is Schroder UK Public Private Trust (SUPP) – formerly Neil Woodford’’s Patient Capital Trust (WPCT) has announced that Link is taking the hatchet to the portfolio net asset value once again. Oh dear……
For all the chatter from certain City folks with degrees in Chemistry, and others, about how a new name and a new management team would transform the fortunes of the Woodford Patient Capital Trust (WPCT), the belated release of the December 31 2019 factsheet shows what a diabolical mess the vehicle now known as the Schroders UK Public Private Trust (SUPP) is in. Is it beyond redemption? Have the City establishment stopped pretending yet?
On today's podcast I discuss Brokerman Dan, the Tory canvasser and the half way house for heroin addicts. I issue a podcast challenge to Justin the Clown as I discuss the joke Vox IPO, I look at a pathetic deadwood press ramp for Woodford Patient Capital Trust (WPCT) and offer up another reason to shut down all open ended property funds. And i have a prize contest for election day, deadline to enter is Monday midnight.
Last week, ShareProphets reader Mark Smith tore a strip off of me for my blasé attitude towards cannabis stocks and drug legalisation. I mean, read that comment: Mr Smith thinks I'm basically Pablo Escobar with a laptop.
On today's podcast I look at Defenx (DFX), Big Dish (DISH), ask whether Mothercare (MTC) is heading for 0p, comment on Versarien (VRS), Kier (KIE), Petra Diamonds (PDL), Egdon Resources and other UK onshore oilers, frackers or not and at Woodford Patient Capital Trust (WPCT)
After a massive writedown in the carrying value of Industrial Heat was imposed on Woodford Patient Capital Trust (WPCT) today, the company is almost certainly more than 20% geared and thus technically in default on its bank loans. It has hyet to 'fess up but you can do the math...
I start by explaining why this bimbo who complained about me in public last night really is a bimbo and why her firm is in no position to complain. Then I look at why Rathbones let down my Aunt Lucy by giving her Woodford exposure - chaps you really need to sign up to a certain website. Then a look at how to value IP Group (IPO) and Woodford Patient Capital Trust (WPCT) and changing manager changes little. Finally I look at the mad woke world of Synthomer (SYNT) as it served up a warning today.
A day of travel adventures. I recount my breakdown last night, an angelic lorry driver and how I ended up on Nigel Somerville's sofa. Meanwhile Darren Atwater is leaving the UK but not ShareProphets. Then I look at utter lunacy from a "woke" FRC and inept Business Secretary Andrea Loathsome. Then it is onto Neil's sacking from Woodford Patient Capital Trust (WPCT), what it means for the Trust and how it will help him hide another £25 million personal windfall gain. I cover Tesla (TSLA) as the bears are squeezed by book cooking. Finally a look at the murky death spiral announced by Vast Resources (VAST).
This regular Sunday feature of the most-read articles of the week has fallen to number 42, so I have pulled out my go-to feature to pull it up for next week: a charticle about cryptocurrency.
I start with a look at who might be sued in the Neil Woodford scandal, focussing in on the directors at Woodford Patient Capital Trust (WPCT). Then I lookl at another mini-bond disaster, this time involving Kevin McCloud of Grand Designs. Finally I discuss the latest deranged thoughts and acts of Chris Frazer of Sirius Minerals (SXX) as he ponders an AIM (sorry main market) delisting. Timber!!!! He is, again, the bears best friend.
Woodford Patient Capital (WPCT) - Neil Woodford's last investment fund still standing, although not for long as he is working his notice - has announced its latest NAV per share. If I were Susan Searle, Chair of the Board, I would be a tad concerned.....
Yes Neil, I will be the guy turning up at some point today in a blue van at your luxury HQ to take some photos and maybe shoot a short video. My pal Nigel Somerville may be coming too. It will be good to catch up. See you later! In the podcast today I also look at Woodford Patient Capital Trust (WPCT), backing Richard Jennings at Global Resources Investment Trust (GRIT) and at Optibiotix (OPTI). I also receive complaints about my coverage of Neil yesterday. I despair.
How I remember being singled out by name by Neil Woodford at the Woodford Patient Capital Trust (WPCT) AGM as a purveyor of fake news on May 16 this year. Neil was adamant: he was doing brilliantly I was making thisngs up. Today he was fired by his flagship fund and his City career is in its final weeks and will end in disgrace. Investors who ignored four years of warnings on this site will have lost billions. I reflect on all of this, where it leaves various parties including Neil's other vehicles, disgraced Hargreaves Landsdowne (HL.) and other disgraced promoters. I also comment on another vindication, the mercy takeover of Brady (BRY) at just 10p after I forced it to fess up to its finacial woes, with the shares at 26p just three weeks ago.
Neil Woodford has been fired from his flagship Equity Income Fund today, vindicating our more than 1000 articles and podcasts exposing him since 2015, but his problems do not end there. I recently commissioned a resting fund manager to produce a detailed bottom up analysis of Neil Woodford’s Patient Capital Trust (WPCT). That report from a man known as “The Badger” landed with me last night and is shocking in its conclusion: the Trust is essentially worthless. The Badger writes:
Recorded in my car in the City where Neil Woodford's crumbling empire is based I flag up something bad about Woodford Patient Capital Trust (WPCT) and discuss why sacking Babcock's (BAB) FD is a pointless gesture.
At the Woodford Patient Capital Trust (WPCT) AGM this year that scallywag Neil Woodford suggested that if I had any interest in beating the disease that would incdeed kill my dear Uncle Chris within weeks, that is to say cancer, I should be getting behind the joke company Rutherford Internationbal (RUTH) into which he had spunked vast amounts of other folks cash. This is a common meme among shameless promoters.
I start, to annoy NoGold, by describing another hidden gem we have revealed at the Welsh Hovel. Then it is onto Castleton (CTP), Bahamas Petroleum (BPC) and Woodford Patient Capital Trust (WPCT). If, like the Sith Lord Zak Mir, you are going to the AIM Awards Dinner tonight just remember who ultimately has paid for your gluttony.
Yesterday the FTSE All-Share, Neil Woodford’s benchmark for his Equity Income and Income Focus unit trusts, put on 0.43% but his funds put on just 0.22% and 0.28% in NAV per unit respectively. It is a familiar story – when the market rises he rises less and when the market falls Woodford funds tank. Whilst the market his recovered a little from its wobbles of last week, Woodford Equity Income’s total value still sits below the £3 billion threshold, having been £3.7 billion when it was gated. And Neil continues to charge his management fees.
I am indebted to Pierotlunaire for his post over the weekend on my piece Woodford Dog BenevolentAI: as predicted......but it is good news really! for the paperwork for Temasek’s investment into this cash-hungry dog has arrived at Companies House and as expected Temasek has take its pound of flesh.
The “good news” for Neil Woodford was that BenevolentAI had managed to attract an investment of $90 million from Temasek. The valuation of BenevolentAI was hit for six, dropping to around $1 billion (from $2 billion) but the other piece of good(ish) news for Neil was that this would drop his unquoted investments held in his Equity Income Fund, which was at the time well over its limit of 10% of the fund – partially because the dodgy Guernsey listings had been scrapped. But of course it also meant that book value of his investments in BenevolentAI had halved at the stroke of a pen.
The Daily Telegraph's lamentable Questor column has today, finally, as you can see below, advised folks to sell Neil Woodford's Patient Capital Trust (WPCT) at a loss of 60%. Talk about horses and stable doors! It gets worse.
Yesterday the FTSE All-Share, Neil Woodford's benchmark for his Equity Income and Income Focus unit trusts, dropped again - this time by 0.64%. But as predicted yesterday, the Woodford funds scored much worse with drops in NAV per unit of 1.83% and 1.56% respectively. The latest drop pushed Woodford Equity Income (WEIF) down to £2.93 billion in total funds - a whopping drop of 21% from the £3.7 billion it sat at before it was gated four months ago. And just so that we do not miss out WPCT, I see that The Telegraph has dumped it this morning.
Well that only took four days – well done Woodford Patient Capital (WPCT) and its Chair, Susan Searle. On Monday it announced the appointment of Mr Raymond Abbott as a new director – but got one of his former companies wrong, missed out another and has still neglected to mention that Foresight 4 VCT suffered a £30 million accounting error on his watch as chairman of the audit committee,,an error under FCA investigation, and a further £3 million accounting error after he was rewarded for his outstanding service and promoted to Chairman of the company.
My cats are on a roll, It is horrfic. I mention this at the start just to annoy NoGold. Them ouzo for Nigel as Woodford Patient Capital Trust (WPCT) fesses up on a fake RNS. But it is still stuffed. I look at Bahamas Petroleum (BPC) as it dissembles, Brady (BRY) whose shares should be suspended, Clear Leisure (CLP) and a joke deal and Ted Baker (TED) which seems fecked.
On Monday Susan Searle, the Chair of Neil Woodford's Patient Capital Trust (WPCT) announced the appointment of Raymond Abbott to the board. This was part of a strategy of renewal as she tries desperately to restore market confidence in WPCT, whose shares are trading at around a discount of one third to its stated NAV, a NAV which has collapsed this year. I have already pointed to the £30 million accounting error at Foresight 4 VCT under Mr Abbott’s watch at chairman of its audit committee, the shambles at Climate Change Control (which WPCT reported as plc when it was a limited company, and we are still yet to see a correction) and a further accounting error of around £3 million at Foresight 4 after he was promoted for doing such a fine job as chairman of its audit committee to chairman of the board. You could not make it up. But it seems that WPCT has not only listed the wrong name of one if his companies, it has missed another off altogether!
Having mentioned two major blunders already, it seems that new appointment Raymond Abbott to the board of WPCT (whose previous directorships are yet to be corrected by WPCT) has another major blunder on his hands – and it is back at Foresight 4 VCT where, having presided over a £30 million blunder as chairman of the audit committee (and he a trained accountant) he was promoted to Chairman. Let us now turn to the FY18 accounts of Foresight 4……
Susan Searle, Chair of Woodford Patient Capital Trust (WPCT), really does have some explaining to do as WPCT released its half-year numbers to the market this morning – reporting deadline day. Quite apart from the shocking performance of the fund under her watch, and the total mess it is in, we have been treated to an admission that the quoted NAVs released by the company have, quite simply, been wrong - a work of fiction.
Further to this morning’s bombshell over the appointment of Raymond Abbot to the board of Woodford Patient Capital Trust (WPCT), it seems that the board of WPCT itself needs to issue a correction as it got one of his former companies wrong. Indeed, whilst it is at it, perhaps it would like to offer some explanation of his tenure at Climate Change Capital which appears to have ended in ignominy, for it appears that Foresight 4 was not the only shambles on his report card.
In today's podcast I discuss Brady (BRY), Mobile Streams (MOS), Woodford Patient Capital Trust (WPCT) and its financially illiterate advisor Nomates, Sirius (SXX0 and Bahamas Petroleum (BPC)
Woodford Patient Capital Trust (WPCT) has results tomorrow. There is talk that Britan's most conceited fund manager may be fired but if Susan Searle and her fellow directors think that gets them or the company off the hook, she is badly mistaken. PS. There is a joke for NoGold 30 seconds in.
Okay I too mention how my beloved West Ham disgraced themselves last night. I was there. It was awful. A long drive home. This morning I tried doing business with St James Place (SJP). What a nightm are! is there an honest IFA who can help me with a simple problem? I then look at Woodford Patient Capital Trust (WPCT), Big Sofa (BST), Eve Group (EVE), Xaar (XAR) and what the shock news from Shore Capital (SGR) says about the state of the AIM Casino.
The Independent Newspaper thinks that I and 17.4 million others need a better education. Does anyone read that rag anymore? In today's podcast I look at Neil Woodford's Woodford Patient Capital Trust (WPCT), notably its holdings in Autolus and Purplebricks (PURP) in light of data out today, Eve Group (EVE), Nigel Wray's Simba, Thomas Cook (TCG), i3 Energy (i3E) and Iconic Labs (ICON).
Oh dear. Oh dear. That’s another fine mess you’ve got me into say unit holders in the Equity Income Fund (EIF) and shareholders in Woodford Patient Capital Trust (WPCT) today as hapless Neil reveals another £12.5 million black hole.
In today's podcast I look at the latest news from AIM bad boy Management Resoiurce Solutions (MRS) where I think my critics really do owe me an apology (again). Then at Neil Woodford's latest woes at the Woodford Patient Capital Trust (WPCT) which are the beginning of the end. Will I get to monster the board at an AGM in 2020 as I did this year? I fear I may be denied that entertainment.
Woodford Patient Capital Trust (WPCT) has today issued a shocking statement “Debt facility”. It shows that its banks ae now getting nervous and pulling all the strings. Boy, Neil Woodford must be glad that he has already sold most of his shares. The news also has grim implications for the Equity Income Fund.
Woodford Patient Capital Trust (WPCT), which is considering Neil Woodford’s future as manager, announced its NAV as at the close of play of Friday this morning (just) at 11.57am. We had been warned that Link was marking down the value of investee Industrial Heat by the equivalent of 3.4p per WPCT share. But it seems this was not the only bad news….
This looks like a doddle to investigate. The stock is ADM Energy (ADME) but will the FCA dare to challenge Shaikh Ahmed Bin Dalmook Al Maktoum or is insider dealing just an offence of you are a nobody? Then I look at the Eddie Stobart (ESL) fraud debacle, the Industrial Heat shambles, Woodford Patient Capital Trust (WPCT), the Equity Income Fund (which has today insisted it will look to ungate at Christmas... whatever) the Income Focus Fund (soon to be gated) and what today's news says about the stupidity, arrogance and lack of ethics of Neil Woodford himself. Postscript: His Highness Sheikh Ahmed bin Dalmook bin Juma Al Maktoum is not to be confused with Sheikh Ahmed bin Saeed Al Maktoum, Chairman of Emirates and indeed a very wealthy man. I did confuse him but this is still a Dubai Royal, will the FCA take him on?
Hat tip my esteemed stockbroker, I flag up a major red flag for global equity markets. I discuss a hot rumour of the real reason the FCA swooped to shut down broker SVS. I look at Canadian Overseas (COPL), Avanti Communications (AVN), Sound Energy (SOU), Woodford Patient Capital Trust (WPCT) and Brady (BRY).
In today's podcast I point fingers at who should be sent to jail or drummed out of the City as I look at new developments at former AIM Casino darling Frontera (FRR), the late lamented SVS Securities and at the crumbling empire of Neil Woodford and Woodford Patient Capital Trust (WPCT).
In today's bearcast I touch on the antics of two of the City's brightest lights. First up is Agronomics (ANIC), where my old friend Jim Mellon is the largest shareholder and the price of cultured pork sausages in 2021, then it is onto disgraced Neil Woodford and Woodford Patient Capital Trust (WPCT).
Two bits of news from Woodford Patient Capital Trust suggest that Neil Woodford is on his way out – or at least believes he is. Firstly, the Board at WPCT intends to tout third-party managers which may or may not result in a change of manager. But secondly, Neil has been dumping his own shares in WPCT – apparently to meet personal financial obligations, including a tax liability. Given that he has trousered tens of millions of pounds from Woodford Investment Management (WIM) over the last few years, that sounds like utter hogwash to me.
Adding to my joy it is off to the mother-in-law's for her Birthday. One lawyer's letter was on behalf of Julie Meyer. I have reported Ms Lingerie on expenses and her lawyer to the North Wales Police in response to the letter you can see here. The other was from Stifel Europe. I discuss Stifel's letter concerning Yourgene (YGEN), Stifel's dire coverage of Woodford Patient Capital Trust (WPCT) and then how Sir Douglas Flint of IP Group (IPO) - a big short - has come out to bat for Neil. Extraordinary.
In today's bearcast I look at more toxic behaviour at Anglo African Oil & Gas (AAOG), at TrakM8 (TRAK), Bluejay (JAY) and there is more on Woodford Patient Capital Trust (WPCT) and the, slowly detonating, nuclear grenade that is Proton Partners (PPI). I also look at (bad) news from Asos (ASC) and Sosandar (SOS) and wonder if there is something happening in online shopping that we have missed.
At 57.3p the shares in Woodford Patient Capital Trust (WPCT) trade at bang on a 30% discount to stated NAV. There has been an enormous amount written about the Woodford fiasco since it started to unfold but a couple of points are worth making...
In the first half of this podcast as I look at UK Oil & Gas (UKOG), Angus Energy (ANGS), Brockham, Horse Hill and the Weald Basin ramp I am joined by comrade Brokerman Dan. Then, alone, I look at Woodford Patient Captal Trust (WPCT) including the key missing info in today's bullshit RNS, Costain (COST), Versarien (VRS) and Mirriad (MIRI).
I asked the question in bearcast - had Woodford Patient Capital Trust (WPCT) burst its overdraft limit? Nigel Somerville thought it had. The PR has got back and it has not. But it is darn close and the answer is actually even more worrying. Let me explain.
In this bearcast I ask a series of questions for PR spinners for Woodford Patient Capital Trust (WPCT). References to 210p should be 227p. Let's see what answers I get. I also look at Optibiotix (OPTI), RM2 (RM2), Mysale (MYSL), Agronomics (ANIC) and have a big question for Neill Ricketts and Versarien (VRS)
Lucy White of the Daily Mail is either the stupidest bint on Fleet Street or takes dictation from WPCT's PR spinners. I discuss her laughable piece on Proton Partners and the stricken Neil Woodford Patient Capital Trust.
The May month-end numbers from Neil Woodford’s funds are out and the numbers at Woodford Patient Capital Trust (WPCT) are really horrible. Just as horrible is that since the end of May the NAV per share has dropped sharply from 89.61p to the current figure of 83.79p – a drop of 6.5% in just three weeks. Bearing in mind that most of WPCT is unlisted, that’s some going.
Sorry for the late podcast but I have spent most of the day renovating another room in the Welsh Hovel. I may post some pictures later but it is far more entertaining than even writing about Neil Woodford's woes or Julie Meyer's lingerie. In today's podcast I look at Thomas Cook (TCG), Audioboom (BOOM), Kier (KIE), Staffline (STAF), Dev Clever (DEV) and the Woodford Patient Capital Trust (WPCT), where, of course, I remain a loyal shareholder. Ho. ho. ho.
A recording glitch. The hot rumour is at 20 minutes, ignore the gap beforehand. Elsewhere, I look at Neil Woodford, Woodford Patient Capital Trust (WPCT), Eve Group (EVE), Xeros (XSG), RM2 (RM2), Hargreaves Lansdown (HL.), BlueJay (JAY), Thomas Cook (TCG) Agronomics (ANIC) and the sodomising of Mail on Sunday reader;s portfolios by prize shit Ben Harrington and at Avereso (ASO).
I see that the spin doctors for Woodford Patient Capital Trust (WPCT) told their poodles in the deadwood press (the FT) to run a fake news article suggesting that vultures were circling looking to bid for the company and its assets. No-one, not even the PR cocksuckers at the Financial Times, believes that for a minute and the shares have slumped again today to 59p, despite, or perhaps in part because of, the weediest of statements from WPCT.
I start this podcast with a look at some of the shite press coverage of the Woodford scandal today, notably Patrick Hosking in The Times and the Daily Mail. Then it is onto what ios the end game for Neil personally: jail? insolvency of WIM? A lifetime ban from financial services? Another OBE and more tea with his pal David Cameron? Finally I look at Woodford Patient Capital Trust (WPCT) and reach out to fellow shareholders. I wish to call an EGM to sack the board and explain why. can you help me?
As usual with the Woodford fiasco, the regulators step in after the damage has been done. The FCA will be all over it now but were conspicuous by their absence while the warning signs flashed. There is at least something that it could still do to protect the private investor from further damage (I am getting tired of warning people against taking a punt on Woodford Patient Capital Trust (WPCT) to avail themselves of the juicy 30% discount to the daily published NAV)…
Susan Searle, the fragrant chairwoman of Woodford Patient Capital Trust (WPCT), where I am a loyal owner of 10 shares, has yet to respond to my polite letter demanding she suspend the shares, fire Neil Woodford and undertake a strategic review. But events now force me to write again in light of Woodford’s incoherent video of earlier. That suggests WPCT now faces a full blown crisis. The letter follows:
As you may recall I invested £8 to become a loyal shareholder in the Woodford Patient Capital Trust (WPCT) and attended its AGM on May 16 to give Neil Woodford a right duffing up. Woodford misled that meeting and for that, as well as gross incompetence, he should be fired at once. I have written to our great leader, chair Susan Searle with calls for immediate action. The letter is below:
It never rains when it pours, so the saying goes, and for Neil Woodford it must feel like an extended monsoon period at the moment. With his flagship equity income fund struggling against redemptions and poor stock-picks to leave it with two classes of accumulation unit now below the issue price (of five years ago, when everything else has gone up) now it is the turn of Woodford Patient Capital Trust (WPCT) to take a bow.
At the AGM of the Woodford Patient Capital Trust (WPCT) which I attended, Neil Woodford insisted that his teetering fund management empire was suffering because of inaccurate media reporting and he singled out one journalist, my good self, in this respect. One of the things Neil reckons I have made up is that the FCA is monitoring his very serious liquidity crisis.
Firstly a few words on Woodlarks. Your generosity has secured its funding for another year. So thanks to all who supported the rogue bloggers. Photos of myself and other old codgers crossing the line are HERE. If you have yet to donate we need just £690 more to hit £50,000 so please donate HERE. Then it is onto Woodford and taking out the spin of the stories in today's Sunday Times it looks really grim and I explain why it could be end game by early July and also why I think we loyal Woodford Patient Capital Trust (WPCT) shareholders were misled at the recent AGM.
So much for Woodford’s problems being the nasty press! Only this week, Neil Woodford was complaining bitterly about all these nasty hacks out to destroy his reputation at the Woodford Patient Capital Trust (WPCT) AGM which our very own Tom Winnifrith attended. But MorningStar is a different kettle of fish and its analyst has put up a new report on Woodford’s Equity Income Fund (EIF) which is, quite simply, devastating. In the light of the new report, I would suggest that even the most sycophantic IFA cannot recommend to its clients that they leave cash in this fund. Prepare for an even greater tsunami of redemptions.
Today's bearcast is a full report on the AGM of Neil Woodford's Woodford Patient Capital Trust (WPCT) which I'd score as a win for me against the great fund manager and his chairman Susan Searle. I did manage to get Cheryl Cole into the debate and I did ask Neil woodford to donate to rogue bloggers for Woodlarks, as you can do here,, but I also took the board to task on a number of other matters and managed to get Neil pretty riled. Happy days.
The £2 billion valuation of Benevolent AI flatters the NAV of Woodford Patient Capital Trust (WPCT), whose AGM I shall be attending this morning, and has - on its own - earned Neil Woodford c£2 million pa in management fees as a result of the EIF Holding. We have covered this Theranos in waiting many times HERE. But what is the scientific view?
At 10.30 AM tomorrow I shall be in the City of Lost Causes for the AGM of Neil Woodford’s investment trust dog Woodford Patient Capital Trust (WPCT) where, as the loyal owner of 10 shares, I have a few questions for Britain’s most conceited fund manager.
I start with missing cat news - it is mixed. Then I look at Optibiotix (OPTI) answering reader questions on gross margins, Management Resource Solutions (MRS), Bidstack (BIDS) Metro Bank (MTRO), BCA Marketplace (BCA), Alien Metals (UFO), Bould Opportunities (BOU), and an apology on Woodford Patient Capital Trust (WPCT). Now, to the 80% of Bearcast listeners yet to do the decent thing, please donate HERE. We are now at 38% of our target so all donations welcome as young Steve Moore says he may join the rogue bloggers.
In today's bearcast I cover Optibiotix (OPTI), Vela (VELA), Woodford Patient Capital trust (WPCT), Ascent Resources (AST), Mosman Oil & Gas (MSMN), Management Resource Solutions (MRS), Bidstack (BIDS) and Optiva/Novum and a hot City rumour. Also I have a message for 90% of listeners - please be a hero today, my 21 mile training walk for this weekend has been planned so donate to Rogue Bloggers for Woodlarks HERE
I start by talking you through yesterday's Odd One Out contest explaining the schoolboy error made by Nigel Somerville and others. I look at the Autolus news in relation to Woodford Patient Capital Trust (WPCT) where as a loyal shareholder I shall be attending the May 15 AGM in Oxford with a few questions for Neil "nomates" Woodford. I flag up a shocking little episode at Clear Leisure (CLP) which should make you worry about Octagonal (OCT) and Inspirit (INSP) given that their FD is disgraced Niliesh Jagatia then discuss Management Resource Solutions (MRS) and finally, in detail, Toople (TOOP). Tomorrow I really will read out a Woodlarks heros roll call. Please join that list ahead of then HERE
Happy Birthday Dad. I hope that you enjoy your "medicinal" apple based gift. I am about ten days from moving house and have just completed a mail relocation form so I shall get my postal vote for the Euros forwarded. I dislike many of the creeps who surround Nigel Farage but his Brexit party has my vote in the bag and I explain why. I look at Management Resource Solutions (MRS) as another red flag emerges for this insolvent piece of crap. I cover Westminster Group (WSG) run by loathsome swine Tony Baldry, Audioboom (BOOM), Woodford Patient Capital Trust (WPCT) and his other dogs and Purplebricks (PURP) in a Joshua interrupted podcast.
The threat of a photo of Dan Levi's Y Fronts post sore bottom training walk remains, so please donate to Rogue Bloggers for Woodlarks HERE. In today's podcast I look at Condor Gold (CNR), the struggling explorer backed so heavily by my good friend Jim Mellon. It looks to be in real trouble. Then good news for Neil Woodford. As of today I am a loyal shareholder in his Patient Capital Trust (WPCT) and looking forward to the AGM greatly. I have a favour to ask of bearcast listeners living close to Oxford who fancy a day out in the City of Lost Causes in late May or early June.
I suggest listening to my Neil Woodford scandal bonus bearcast first HERE but I have another bone to pick with Susan Searle, the chairman of Woodford Patient Capital Trust (WPCT) on how she has screwed investirs today. Then I look nat Red Emperor (RMP), 88 Energy (88E), Pantheon Resources (PANR) and at Cabot Energy (CAB). Finally a look at the latest woes at Revolution Bars (RBG) - you really would have thought that Britain's thirstiest share blogger would have nailed this as his specialist subject but it appears not. If you enjoyed this podcast please support the EIGHT rogue bloggers for Woodlarks with a small donation HERE
Today we have news of a shocking transfer of unquoted crap from Woodford's flagship Equity Income Fund to Woodford Patient Capital Trust (WPCT). It may keep the FCA at bay on one point for a while but it is a joke that only serves to create fresh problems. And the RNS is misleading to boot on the issue of cash. Or lack of it. As I noted yesterday, the FCA would not tolerate this nonsense from any other fund manager but its pressure is forcing Nomates to act in an increasingly desperate manner. If you enjoyed this podcast please support the EIGHT rogue bloggers for Woodlarks with a small donation HERE
Eight days ago Neil Woodford’s PR spinners told their gophers in the lacky corrupt deadwood press, aka Peter Evans and Sabah Meddings of the Sunday Times to write a big puff piece about how Neil Woodford’ backed Proton Partners was planning to raise £50 million and list on the NEX lobster pot. It has not taken long for that fake news to be exposed, as no investors other than Woodford himself have been prepared to back this IPO – something revealed in the prospectus out today.
Woodford Investment Management has published its latest monthly numbers to the end of January from its Equity Income, Income Focus and Patient Capital Trust. At first glance it does not look too bad, but a more detailed examination shows that debt remains a central issue, as does redemptions, and Woodford Patient Capital Trust (WPCT) seems on the edge of imploding.
Noting that one of Neil Woodford’s earliest investments for Woodford Patient Capital Trust (WPCT), Verseon (VSN) – trading on AIM but a US biotech outfit in the disruptive space (natch) – appears to be headed for trouble I commented that at least the company has the services of the good Xavier Rolet (yes, the former LSE boss!) on the board. So all’s well! Well, it was until this morning! Oh dear….
I start with a detailed look at Neil Woodford's debt crisis at his Patient Capital Trust (WPCT) as exposed by Nigel earlier and explain what happens next. Then prompted by my Blue Jay (JAY) article I look, using various case stiudies, at how a CEO on AIM gives you a clear steer that he is not going to do a placing when he is going to do exactly that.
An appertion came to me last night: it was the ghost of Cynical Bear, calculator in hand, telling me that the level of borrowing at WPCT has become a major problem for Neil-knows-best Woodford. And indeed it is: as at the end of December Gross Assets (ie before bank borrowings) stood at £969 million, according to Woodford. With net assets of 97.61p per share and 827 million shares that works out at net assets of £807 million and that means borrowing of a whopping £162 million, or 19.6% of NAV. Yikes!
A note from the celebrated Cynical Bear last night got me looking into one of the very first investments made by Neil Woodford for the Woodford Patient Capital Trust (WPCT) – that of AIM-listed Verseon (VSN). Dum dum-dy dum, dum dum-dy dum, you’ll see the Red Flags flying here……Surely this shows all that is wrong with Woodford!
The new KID, or Key Information Document, for Woodford Patient Capital Trust (WPCT) arrived in my inbox this morning. This is an FCA regulated document, and supposedly gives you an idea of the potential returns under various scenarios. It also tells us that it is categorised as number 4 on the risk indicator (up from 3 last time). So let’s see what we might make if we hold the fund for the minimum recommended term.
Woodford Patient Capital Trust (WPCT)or his flagship Equity Income Fund? It is hard to know where to start for we have disastrous news from both today. How close are we to end game for Neil Woodford, a man happy to be described as Britain's Buffett.
In October 2016 Neil Woodford’s Patient Capital Trust (WPCT) spunked £12.281 million with an investment into unquoted cash guzzler Amo Pharma. Amo has belatedly filed its calendar 2017 accounts and it looks grim. Suffice to say Britain’s most conceited fund manager is the sole institutional backer.
In today's podcast I look again at yellow journalism re Woodford Patient Capital Trust (WPCT) as covered HERE and the MySquar (MYSQ) fraud. The corrupt deadwood press is part of the problem not the solution. I cover the latest news from MySquar in case I don't have time for a dedicated article. Today is a Joshua day but I hope to write as he takes a nap. I also look at Mirriad (MIRI), Mosman Oil & Gas (MSMN) anmd Haydale Graphene (HAYD) whose news today means that Nigel Somerville will have enjoyed ouzo on his breakflast cornflakes.
The PR machine of Neil Woodford got its pliant servants at the Daily Mail and elsewhere in the corrupt deadwood press to make great play about how the Woodford Patient Capital Trust (WPCT) was about to go into the FTSE 250 Index so meaning that Index funds would have to buy the shares so the share price would go up. Uh Oh! Late last night came an announcement from the LSE:
Woodford Patient Capital Trust (WPCT) held, as at 30 September, 4.95% of its gross funds in unlisted healthcare stock Immumocore. I say gross funds because WPCT has taken on rather a lot of debt over the last while – presumably because Woodford ran out of cash and still had too many hungry mouths to feed. If the entire portfolio goes a load higher then of course being leveraged is a good thing. Unfortunately, it is a bad thing if the portfolio keeps of falling in value.
Slightly belated update on the end-September portfolio listings this month but the ‘good’ news is that I am no longer fighting this battle alone and a small, parochial rag called The Financial Times has started to pick up on the issues, although they don’t get all the story, natch!
Just when you don’t think that the goings-on at Woodford Patient Capital Trust (WPCT) can get any more surprising, an RNS comes out of nowhere to make everything right in the world, relating to the unloved holding Industrial Heat. It seems that Neil Woodford can bend the laws of physics after all!
Following my piece this morning on Woodford (HERE), I note that Woodford Patient Capital Trust (WPCT) published its interims at the rather odd time of 9.45am today which ruins my competition to some extent. Anyway, there is some good news in there that I am happy to report but it still begs a few questions that I am also happy to ask in my general nit-picking way.
With the end-August portfolio listings coming out yesterday, it is time to update the story and it is not looking any rosier. In fact, quite the reverse. I think matters may be coming to a head here and I reckon Woodford needs a lucky break for once and pretty damn quickly.
Following the poor trading update last week from RM2 International (RM2) that I covered HERE, its interims were issued this morning and are largely as expected but still worth a quick look and it’s time to place your bets as to whether Mr Woodford is going to throw another $17 million in to the pot.
Nice of Tom to set me up for this one today with his preview yesterday (HERE) and, to no-one’s surprise whatsoever, Xeros Technology Group (XSG) published its interims this morning showing continued significant cash-burn and a need for another chunk of dosh from Mr Neil Woodford and his pals.
To emphasise the point about the contrasting investment strategies of Neil Woodford and Terry Smith that I covered earlier today, I thought it appropriate to cover the health-tech AI spoof, BenevolentAI, that has just filed its results for the year to 31 December 2017 at Companies House (HERE). I am still struggling to find any evidence of anything other than a reasonably good concept here.....and it’s meant to be worth $2 billion!
It is hard not to compare these two behemoths of the UK fund management industry. Neil Woodford has (still) a great long-term track record but the recent respective performances of their flagship funds are chalk and cheese and now Terry Smith is looking to encroach on Woodford’s territory further with a small company investment trust too.
Woodford’s month from hell has got off to a strong start with an immediate dog’s dinner of a revenue/profit warning from uber-dog RM2 International (RM2) this morning. Let’s take a closer look and count up all the negatives.
I smiled at yesterday’s announcement from Woodford Patient Capital Trust (WPCT) summarising the “summer of milestones” achieved across the portfolio as I imagine that is just buttering up the audience before the bevy of bad news hits. From my point of view, September is going to be a hellish month for Mr Woodford so welcome to ‘I-Spy Woodford’s September Hell’
There is good news for Woodford Patient Capital Trust (WPCT) in the end-July portfolio listings that came out yesterday, ironically due to a bit of help from the Woodford’s flagship fund, the Equity Income Fund. More interestingly, I think I have finally worked out how the Equity Income Fund is getting round its 10% unquoted stock limits which makes shocking reading if correct.
Turning to my third, and the most recent, quoted constituent of Woodford Patient Capital Trust (WPCT) this weekend, I thought I should give a warm welcome to Sensyne Health (SENS) that joined AIM on Friday at a very nice valuation indeed. It’s good to see that the words ‘healthtech’ and ‘AI’ are able to suck in as much dumb money from the markets these days as the word ‘blockchain’!
Continuing my leisurely weekend stroll through the cash-guzzling listed stocks in Woodford Patient Capital Trust (WPCT), I’ll look at his second Norwegian dog, Thin Film Electronics, as its half year results came out yesterday.
Neil Woodford doesn’t have many quoted stocks in Woodford Patient Capital Trust (WPCT) but I thought I’d look at three classic picks this weekend, two of which I’ve touched on before, the third being a brand new entrant. I’ll start by catching up with the two Norwegian quoted companies in the portfolio – first up, Idex.
I appreciate that the heading seems like a bold claim with such stiff competition but with Atom Bank putting out its results or the year to 31 March 2018 this week, I do think it is a serious contender.
Having looked at Woodford’s Equity Income Fund earlier, I will now turn to Woodford Patient Capital Trust (WPCT) which as ever, even though the goalposts keep moving, is up against its limits and with the portfolio remaining awash with cash guzzlers, I’m struggling to understand how Neil Woodford gets out of the mess.
With the end-June portfolio listings coming out yesterday, I thought I would update with a couple of pieces looking at each of the two major funds. First up, I’ll look at the flagship fund, the Equity Income Fund, where continuing redemptions necessitate exiting one of the better stocks completely leaving a greater proportion of dross behind.
I’ve touched on Immunocore a few times in passing as it one of the largest holdings in Woodford Patient Capital Trust (WPCT) as well as being the largest investment made by Dublin-listed Malin Corporation, of which Woodford is the largest shareholder, obvs! Well, it looks like it’s not a particularly happy ship and I wonder whether a (further) devaluation is required?
It’s undoubtedly been a good week for Neil Woodford, with the Autolus IPO getting off to a flying start and I also sense the Stobart tussle is moving in his direction too. Nevertheless, as I’m still in a grump about his shoddy debt non-disclosure last week, I thought I’d have a look through the Woodford Patient Capital Trust (WPCT) portfolio to see what else I could find as he’s always banging on about unicorns hiding in there somewhere.
Yesterday afternoon, Neil Woodford released his end-May portfolio updates and associated fund factsheets which highlighted the challenges facing Woodford Patient Capital Trust (WPCT) in the coming months as its debt position is now almost untenable, not that Woodford has disclosed as such.
In today's podcast I cover in detail Telit (TCM) and also look at MySquar (MYSQ) partially in light of today's stunning news HERE. I look at Audioboom (BOOM), Frontera (FRR), Woodford Patient Capital Trust (WPCT), Prime People (PRP) and 88 Energy (88E). Tomorrow I will be bored to death by Lucian Miers, he will drone on about West Ham for 6 hours as we complete a 19 mile training walk from Bristol along the Avon to a few miles past Bath. I am building up to my 32 mile walk for Woodlarks with Brokerman Dan on 28 July. Think of my suffering tomorrow and please donate a small sum HERE.
As I’m always quick to criticise, I thought it only right to congratulate Mr Woodford when the rare pieces of good news turn up and Autolus’s news yesterday is undoubtedly good news although I’m still going to make a couple of observations re Woodford Patient Capital Trust (WPCT).
I’ve always thought it odd when investment vehicles merely take stakes in other investment funds as one ends up with duplication of fees. There is usually an investment policy limit on such stakes, not that Mr Woodford appears to be taking the limit at Woodford Patient Capital Trust (WPCT) that seriously. Why would he - rules are for the great unwashed aren’t they?
I’ve been meaning to write about the outrageous risk profile assigned to Woodford Patient Capital Trust (WPCT) for a while as it is patent nonsense and dangerous. I wonder whether there could be a mis-selling claim waiting to happen here.
The first part of this mini-series highlighted oddities relating to the recent $2 billion valuation of Benevolent AI, Woodford’s largest unquoted holding. To complement that piece, I thought I would undertake a bottom-up analysis to understand whether it could be worth such a sum. All I found was more spoofery. It’s a bit of a long read but surely you’ve got nothing better to do on Bank Holiday Monday!
I had to laugh last night when I saw PrimaryBid’s pre-Bank Holiday offer to the likes of you and me - Mereo Biopharma (MPH) - as although there’s some stiff competition, I think this must the worst deal offered up to-date and, in fact, worse than the other offer of a lifetime that I’m currently working out how to avoid, namely dinner at the in-laws during the Champions League final!
In my view, Woodford’s dealings with what is now his largest unquoted holding across his funds, Benevolent AI, is his kryptonite and will be his undoing and I’m doing a couple of articles outlining why I think the current $2 billion valuation is an absolute spoof and why I believe Neil Woodford is complicit in said spoofery.
Yesterday afternoon, Neil Woodford released his end-April portfolio updates so thought I’d provide a bit of commentary prior to a couple of headache inducing articles (for Neil) later on in the week. Not a huge amount of change; however, it’s good to see an open-ended fund getting stuck into the use of debt in such a cavalier way!
Woodford Patient Capital Trust (WPCT) recently came out with its disappointing 2017 results and thought I’d highlight a few amusing aspects to try to cheer up shareholders here and ask a few serious questions of the Chairman, Susan Searle.
There’s been a lot to comment on relating to Woodford Capital Patient Trust (WPCT) recently but with the March portfolio updates for all of Woodford’s funds finally being published on Monday, I thought I should get my updates out as Woodford appears to have been a bit preoccupied to do so with a minor biotech blip and the like.
Following on from my piece on Sunday in which I suspected that Woodford had covertly changed the Investment Policy for Woodford Patient Capital Trust (WPCT), it was confirmed this morning in its full year results. This is an absolute disgrace and shareholders should get on to their lawyers.
Just as the tide seemed to be turning in favour of a couple of Woodford’s holdings, he suffered an absolute body blow this afternoon with his largest quoted holding, Prothena (NSDQ: PRTA), which comprised 9.12% of WPCT as at end-March, as it announced that it was discontinuing the development of its main drug and the share price collapsed as a result.
Following on from Tom’s excellent presentation at the UK Investor Show yesterday I thought it only right to continue in my questioning of the “star fund manager” especially as it looks to me as if the Investment Policy for Woodford Patient Capital Trust (WPCT) has been subtly changed (to the detriment of shareholders of course) but Woodford doesn’t seem to have told anyone!
I’ve been wondering for a while how Neil Woodford was going to deal with the impending crisis at his flagship Equity Income Fund in relation to the hard, unquoted stock limit of 10% and with all his Get Out of Jail cards used up. Filings at Companies House seem to indicate that he was left with one last option – giving his shares back to the company at nominal value!
Thanks for the few entries to the Woodford Easter Quiz. Although a couple of people got the odd one out and for the right reason, as I expected, only one person got it right and named all sixteen companies correctly so well done KayeSeraSera (again). A chocolate gift will be winging its way to you, probably in time for Christmas! Full results below.
As today is the day to celebrate resurrection, I thought it fitting to comment on a couple of stocks, namely Sosandar (SOS) and Woodford Patient Capital Trust (WPCT). Despite a difficult first quarter for the pair of them, I expect them to laugh death in the face and crack on from here bigger and better than ever.
It being a major religious festival, I thought it appropriate to serve up another Woodford-related quiz. Simple on the face of it, just tell me which of the sixteen graphs below is the odd one out and why - a full answer is required other than the obvious. A chocolate gift to anyone who can go one better than that and name all sixteen companies. To assist on one of them, the graph is pre-share consolidation earlier this year.
Further to my update piece last week, I’ve managed to take a closer look at the end-February portfolio of Woodford Patient Capital Trust (WPCT) and I just can’t make the numbers work. I can only assume that Woodford has breached his investment policy; let me explain.
Almost three years after launch, Woodford has achieved what would have seemed impossible at the launch of Woodford Patient Capital Trust (WPCT) back in April 2015 in that he has managed to compile a portfolio of 85 holdings without one obviously profitable company among them. Having sold the star of the portfolio in the month namely A J Bell, to keep the lights on and fund a few other future dogs, he’s now left with a whole array of cash-guzzling, largely illiquid dogs – what’s not to like.
Well it only took until 22 March for the end-February portfolios to be updated for the various Woodford funds but quite a lot to cover so it’s a two-parter this month. I’m going to start by looking at Woodford’s valiant efforts in keeping his flagship fund, the Equity Income Fund, afloat. It’s not an easy task dealing with continual redemptions and he has had to ditch an old favourite to do so.
I do hope that the FCA and the "Independent" directors at Woodford Patient Capital Trust (WPCT) look into this matter with some urgency as we appear to have evidence today, thanks to Oxford Nanopore, that Neil Woodford funds have been stating their NAV in an unnacceptably aggressive manner. And that is the most generous spin on what has gone on.
Thanks for all the entries – I’m pleased to be able to say “entries” this time - to my Woodford Cheltenham Festival (HERE). I’m calling it a day early as the result is clear. Read on for the winner and the choice of Cheltenham runners on which I am placing the winner’s free bet.
It’s amazing what can be done when one’s back is against the wall. For the third month running, the guys at RM2 International (RM2) have found some cash from behind the sofa and can put some money in the meter. Its RNS this morning is its most upbeat in a while although I'm not sure it will alter the long-term outcome.
I do try to be balanced from time to time and despite all his troubles, there’s been a few green shoots for Neil Woodford in relation to Woodford Patient Capital Trust (WPCT) in recent weeks, most notably with a substantial round at Atom Bank…….although much more funding is still required.
In my conclusion to The Big Short series on Woodford Patient Capital Trust (WPCT), I wondered where new pools of capital could come from to keep these biotech valuations afloat now that Woodford has run out of money and I considered capital from China as a potential life-saver. Two pieces of news this week make me consider this further, one in relation to another long-term short pick of mine in the biotech fund space, namely Arix Bioscience (ARIX).
Vernalis (VER) raised the white flag in its RNS yesterday morning and it is no great surprise to see Woodford and Invesco dominating the shareholder base. I hate to think how much Neil Woodford has spent on this dog over the years, but I’m going to see if I can work it out.
"Why Woodford has NOT lost his magic touch... despite UK's star stock picker seeing a series of huge bets going wrong spectacularly". So screams the headline on a leading article by Paul Thomas in the Daily Mail. I suppose it depends on how you define magic? If you mean it is making things ( like other people's money) disappear then indeed, Nomates is still the King. Why was this article written?
As Neil Woodford is such a believer in transparency, he has pulled his monthly updates altogether so these monthly updates now take on a greater importance to provide much needed information to the long-suffering investors in the three funds. Can’t imagine why Woodford stopped them?
Loyal readers will know that I, like Mr Woodford, love a quiz and with my favourite week of the year fast approaching, I thought I’d run a (simpler) quiz with a Cheltenham-related prize. There’s only two questions, so I’m hoping for more than one entrant this time!
I would urge anyone interested in these Woodford stock stories to read the sister Norwegian piece relating to Thin Film Electronics first as the similarities are astounding but it is worth covering Idex in its full glory. Yet another horror show.
I appreciate that Steve covered the highlights HERE but it is worth providing a bit more information on yet another yapping Woodford pug as the tale is all too familiar and one that will no doubt be repeated again and again in the future.
UPDATED: Over the weekend I revealed a potential nuclear landmine that could well blow up the Woodford Patient Capital Trust (WPCT).The bad news for the asleep at the wheel nmot so independent NEDS at the Trust is that I have found two more landmines which have been averted but are there more?
At 31 December 2017, Ombu Group represented c2.02% of the Woodford Patient Capital Trust (WPCT) portfolio being two separate investments of 2.01 % + 0.01%. The principal activity of Ombu Group, according to its accounts, is providing capital and management support to fast growing companies in the fields of industrial technology, energy technology and water technology.
After much digging and talking to those in the know I have managed to piece together how Neil Woodford and his team assess potential investments and have actually managed to access a transcript of a recent investment meeting that makes very “interesting” reading!
CityAM announced earlier this week that Woodford’s Equity Income Fund had lost a billion quid in funds since the start of the year down to £7.2 billion. This has huge consequences for all his funds and I’m not sure he has enough arms to suppress all the troublesome blind burrowing mammals raising their heads above ground. For the avoidance of doubt, I am referring to metaphorical moles at this point rather than Woodford’s investment diligence team. Let me explain.
I start with why this bearcast is late. I got back very late from London where I was watching my daughter play Harold Wilson in Made in Dagenham and she was brilliant. So too was the musical. Well done Olaf although you are wrong about the gender pay gap! I look at the market bounce and the shit that is leading it. I look in real detail at the trading statement at Reach4Entertainment (R4E) where I am a shareholder, at Woodford dog RM2 (RM2) which is going on a one way trip to the vets in a fortnight and also at Woodford Patient Capital Trust (WPCT). Post bearcast it announced its NAV at 85.93p which means gearing must surely be through the 20% barrier. I also look at Optibiotix (OPTI) and the warrant exercise issue.
You will have read our detailed coverage of Neil Woodford's woes and especially those of his uber dog listed investment company Woodford Patient Capital Trust (WPCT). Our sell advice has saved our readers thousands of pounds. But we believe in balance and so below is the advice of The Times Tempus column which is to buy. It is poorly researched - compare its coverage of Atom Bank with ours HERE) for instance and reads as if it was dictated by a PR person as is so often the case with the stinking carcass that is the deadwood press. Here goes...
I’m not normally one for emotive comment but my “Big Short” thesis at Woodford Patient Capital Trust (WPCT) is playing out almost exactly as I anticipated, albeit more quickly than I imagined, and it is an absolute scandal, make no mistake. All shareholders should be seeking redress and recompense immediately. Let me explain.
As we await today's NAV from, deep in the merde, Woodford Patient Capital Trust (WPCT) as well as possible confirmation its unquoted holdings have surged through the 80% limit as well as potentially news on how close hitis to breaching the bank limit of 20% gearing, it is worth reminding ourselves of one reason why it is in this mess - its high risk approach to leverage.
As predicted here at the weekend Nasdaq listed Irish biotech Prothena (US:PRTA) is suffering a bloodbath today following the shock after hours resignation of its CMO on Friday. Shares in Purplebricks (PURP) are also crashing and that leaves the Woodford Patient Capital Trust (WPCT) in serious trouble - has it breached its banking limits yet?
Pointed in its direction by Robert Dwek in the comments on my last Woodford piece, I thought I would write an article on the hugely capital intensive Woodford portfolio holding, Atom Bank, a start-up bank. A bit of a long read but I found it quite intellectually interesting looking at the challenges facing a start-up bank and it also throws up one of the first major funding issues for Woodford caused by the predicament he has recently got himself into.
Thought I may as well stick to a theme today and look at another Woodford investment which, surprise, surprise, undertook a placing on Friday, Dublin-listed, Malin Corp. This is yet another fund that invests in the same sort of early-stage biotech plays as Woodford Patient Capital Trust (WPCT). I will touch on why it looks overvalued to me and leave you with a piece of analysis to highlight the odd incestuous world of these biotech investors not that I’m making any accusations of course.
Hapless Neil Woodford has poured out his heart to the poodle press, Citywire, bleating about how wicked bears Kerrisdale have been beastly about one of the largest - and most obviously overvalued - of the pack of dog investments in his Woodford Patient Capital Trust (WPCT). The bears have bitten back!
I don’t apologise for banging this drum a bit more in the context of Woodford Patient Capital Trust (WPCT) as the transactions relating to Benevolent AI just look so wrong and WPCT shareholders should be fuming and raising hell. I also have a few more facts to share and two additional interesting pieces of information – one new, one old.
As I anticipated in my RM2 International (RM2) piece yesterday, the December monthly updates finally came out yesterday afternoon and I thought it appropriate to provide monthly updates on The Big Short in conjunction with those each month so here goes. Quick summary: it’s not getting any easier for Woodford.
Look, I’m trying to be nice. We were last told that it could be tits up for RM2 International (RM2) by the end of January and today we heard that it has found enough cash down the back of the sofa to last until the third week of February. Good news! The reality is that this is a cash guzzling uber-dog and highlights the predicament that Britain's most conceited fund manager Neil Woodford has got himself into.
I love Warren Buffett’s quote that you only find out who has been swimming naked when the tide goes out and after Woodford’s annus horribilis in 2017, it certainly seems to be easier and easier to find examples of his commando-style investing (thanks also to the pointer from ‘alcira16247’). Next witness for the prosecution, M’Lud, is Industrial Heat, a business that is trying to invent a “cold fusion” machine, an area of physics that most sane scientists appear to think is something out of a science-fiction novel. Not Woodford though.
In the UK, cannabis stocks are fever dreams of bulletin board morons. Here in Canada, it's respectable news in the quality newspaper financial pages.
I’ve been smiling this week at the comments on Woodford’s website as the moderators are desperately sticking to the party line regardless of what is happening in reality or what Woodford himself is briefing to investors privately. Let me explain in the context of his Income Focus Fund.
I gather that Neil Woodford's office has been busy dealing with questions relating to our most excellent series of articles and podcasts over Christmas. I have been made aware of its responses which are detailed but still leave me feeling incredibly unsettled on two major factors.
I alluded to the swapping of the Benevolent AI stock between the two Woodford funds in my early chapters of The Big Short looking at Woodford Patient Capital Trust (WPCT) but there are so many odd aspects to the saga going back a few years that it merits an Appendix to itself as it raises a number of serious additional questions for the Board in my view.
I made reference in my concluding part of “The Big Short” on Woodford Patient Capital Trust (WPCT) about a potential Appendix or two to deal with some of the detail, so here’s the first providing more information on the WPCT Board Directors which, as Tom has pointed out during his Christmas Eve Bearcast, are not particularly independent at all and there is a significant conflict of interest issue.
I’m going to draw together my analysis on Woodford Patient Capital Trust (WPCT) in one piece now so that if you’ve actually been enjoying Christmas rather than reading Shareprophets, you can start here and work backwards. I will also add a few words of caution that I picked up from the book “The Big Short” itself.
In this bearcast I look at the role of NEDs and their failings in a bull market. that is a general point I then discuss the NEDs at Woodford Patient Capital Trust (WPCT) and how they MUST be replaced at once. The COI are surely too great. I then discuss a woman reduced to tears by charlatan and snake oil salesman Darren Winters this Christmas Eve.This story will horrify you. I then discuss Christmas. Whatever you do, however you spend the day I hope that it is in some way joyous. That magical moment at Midnight Mass as you sing "Yea, Lord, we greet Thee, born this happy morning" and you realise it is Christmas Day is now only hours away.
Er….hi, just me again! This Chapter of “The Big Short” looking at Woodford Patient Capital Trust (WPCT) wasn’t in the original draft manuscript sent to my editor but as something truly astounding was pointed out to me in the comments of my piece yesterday, I thought I’d better add to the opus. Hat tip to Robert Dwek for spotting it.
Having looked at the unquoted risk and the level of debt and connected liquidity issues within the Woodford Patient Capital Trust (WPCT), it is time to look at the tricky topic of valuation policy as it looks to me as if Woodford is taking a particularly aggressive approach, albeit a flexible one, to the valuation of the unquoted stocks (almost all the fund!) that casts further doubts on the underlying NAV.
Continuing my festive series on The Big Short, Woodford Patient Capital Trust (WPCT), having highlighted yesterday the huge unquoted risk within the portfolio and having to clean up after its big brother, the Equity Income Fund, I wanted to turn next to concerns I have over its debt levels which leads on to liquidity issues.
I started my festive series on The Big Short, namely Woodford Patient Capital Trust (WPCT) earlier by providing some wider context about some of the challenges Woodford faces particularly with his flagship fund, the Equity Income Fund, but let’s get into the details of WPCT itself. I’ll start with the ever increasing size of its unquoted portfolio and what appears to me to be a massive conflict of interest.
My Christmas Quiz may have been too clever by half (one entry so far at the time of writing!) but I found it helpful in any event as the research I undertook made me realise that there is massive short potential across the biotech echo chamber participants with Woodford Patient Capital Trust (WPCT) being the best example for a couple of specific reasons. Accordingly, I’m doing a few pieces over the festive period outlining my analysis and raising some serious questions along the way for Woodford to answer. To start though one must provide some wider Woodford context particularly in relation to his flagship fund – the Equity Income Fund.
A week ago, I noted that news was due from the disruptive pallet manufacturer, RM2 International (RM2) and doubted that it was going to be positive. Well, it finally came out yesterday and I wasn’t disappointed although assume Neil Woodford and the long suffering shareholders of this and his Patient Capital Trust (WPCT) probably were.
If I was Neil Woodford I would wake up each Monday morning thinking, for the love of god, please can this be the week with some good news to come out of the Woodford Patient Capital Trust (WPCT) portfolio. Unfortunately, I don’t think it will be this week as it looks like crunch time is approaching for the “disruptive” pallet-maker, RM2 International (RM2).
Answers on a postcard. But for starters, one Hathaway, One had a way but lost it. I start with a detailed look at the Woodford Patient Capital Trust (WPCT) then run some numbers by you on LPE's and Purplebricks (PURP). I mention UK Oil & Gas (UKOG) en passant, Jersey Oil & Gas (JOG), Columbus Energy (CERP), Mirada (MIRA) and finally Conroy Gold & Natural Resources (CGNR)
When Neil Woodford launched his Patient Capital Trust (WCPT) to much fanfare in 2015, everyone waited expectantly to see how he would start spending the £800 million war chest and so one had high hopes in April 2015 with the announcement of the first investment for the fund, namely a £4 million investment in an exciting quoted biotech play, Sphere Medial Holdings (SPHR). As an announcement last night showed, it has been as successful (or not) as one of his other uber-dogs RM2 International (RM2).
If you read the bent, freebie is our middle name, personal financie columnists in the deadwood press, fund manager Neil Woodford walks on water. I disagree and have noted before, that, maybe, after three dismal years, others are starting to see the light. But, with assistance from a leading broker, how about we have a real look at the Woodford Patient Capital Trust (WPCT) but also at the sort of dogs Neil ifalls in love with.
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at Real Good Food (RGD), Tungsten Corporation (TUNG), Woodford Patient Capital Trust (WPCT).